Holen Sie sich die Stockscreener-App
1.77
0.58%
-0.04
Schlusskurs vom Vortag:
$1.73
Offen:
$1.76
24-Stunden-Volumen:
26,762
Relative Volume:
0.54
Marktkapitalisierung:
$6.28M
Einnahmen:
$3,000
Nettoeinkommen (Verlust:
$-4.53M
KGV:
-1.4283
EPS:
-1.2392
Netto-Cashflow:
$-4.69M
1W Leistung:
+1.18%
1M Leistung:
+29.32%
6M Leistung:
-25.22%
1J Leistung:
-74.17%
1-Tages-Spanne:
$1.68
$1.78
1-Wochen-Bereich:
$1.58
$1.78
52-Wochen-Spanne:
$1.16
$6.83
Pulmatrix Inc Stock (PULM) Company Profile
Firmenname
Pulmatrix Inc
Sektor
Branche
Telefon
(888) 355-4440
Adresse
945 CONCORD STREET, FRAMINGHAM, MA
Compare PULM vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PULM
Pulmatrix Inc
|
1.72 | 6.28M | 3,000 | -4.53M | -4.69M | -1.2392 |
VRTX
Vertex Pharmaceuticals Inc
|
524.54 | 134.02B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
672.59 | 68.59B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
920.31 | 58.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
320.12 | 41.76B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
191.85 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
Pulmatrix Inc Stock (PULM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2018-02-09 | Eingeleitet | H.C. Wainwright | Buy |
Pulmatrix Inc Aktie (PULM) Neueste Nachrichten
PULMPulmatrix Inc Latest SEC Filings - Finviz
Enterprise value to EBITDA forward of Pulmatrix, Inc. – NASDAQ:PULM - TradingView
(PULM) Volatility Zones as Tactical Triggers - Stock Traders Daily
Pulmatrix Inc Actuals & Estimates (NASDAQ:PULM) - TradingView
Pulmatrix Inc Actuals & Estimates (LS:A3DWEE) - TradingView
Enterprise value to revenue forward of Pulmatrix, Inc. – NASDAQ:PULM - TradingView
Price to earnings forward of Pulmatrix, Inc. – NASDAQ:PULM - TradingView
Enterprise value to EBITDA forward of Pulmatrix Inc – TRADEGATE:2PU - TradingView
PULM Q2 2025 Earnings: Clinical‑Stage Biotech Reports Loss Per Share of $0.42, No RevenueEBITDA Estimate Trend - dars.gov.et
Price to earnings forward of Pulmatrix Inc – TRADEGATE:2PU - TradingView
Enterprise value to EBIT forward of Pulmatrix, Inc. – NASDAQ:PULM - TradingView
Pulmatrix Inc (PULM) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Pulmatrix Inc (PULM) Institutional Confidence - TradingKey
Pulmatrix Inc (PULM) Valuation: PE, PB & Fair Value Analysis - TradingKey
Pulmatrix Inc (PULM) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Pulmatrix Inc (PULM) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Pulmatrix Inc (PULM) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Pulmatrix Inc (PULM) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Pulmatrix Inc (PULM) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Pulmatrix Inc (PULM) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Pulmatrix (NASDAQ: PULM) posts 2025 loss as Cullgen merger to give Cullgen 96.4% - Stock Titan
PULM Q2 2025 Earnings: Net Loss Reported, Stock Rises as Investors Look Past Revenue AbsenceConsensus Forecast Report - newsline.com
PULM Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Pulmatrix Q2 2025 Earnings: Loss Per Share of $0.42 as Clinical Pipeline AdvancesEarnings Preview - newsline.com
Pulmatrix Q2 2025 Earnings: Net Loss of $0.42 per Share as Biotech Continues Pipeline DevelopmentReturn On Capital - newsline.com
PULM Q2 2025 Earnings: Clinical-Stage Biotech Reports EPS of -$0.42Revenue Inflection Point - newsline.com
Pulmatrix Inc. (PULM) Q2 2025 Earnings: Narrowing Losses Amid Clinical MilestonesCore Business Growth - newsline.com
Preclinical data: PTC-2105 boosts lean mass; Pulmatrix (NASDAQ: PULM) merger on track - Stock Titan
Eos SENOLYTIX Presents Best-in-Class Preclinical Body Composition Data Highlighting Unique Muscle Mass Gains with MitoXcel™ Geropeptide PTC-2105 at the Sachs 2nd Annual Obesity & Cardiometabolic Innovation Forum - GlobeNewswire Inc.
Pulmatrix (PULM) registers 490,910 shares for resale including 36,364 dividends - Stock Titan
Pulmatrix Stock Slides As Eos Merger Clock Starts To Matter For PULM Holders - Bez Kabli
PULM Q2 2025 Earnings: Reported Loss of $0.42 per Share as Company Advances Pipeline - dars.gov.et
PULM Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Pulmatrix (PULM) Gains 1.47% as Shares Approach Key Resistance LevelIntraday Trade Ideas - The Legal Advocate
Pulmatrix Inc. (PULM) Edges Higher as Stock Gains 3.68% – Key Levels in FocusProfitability Factor - The Legal Advocate
Pulmatrix Inc. (PULM) Holds Steady at $1.34 as Key Support and Resistance Levels TightenIsland Reversal - The Legal Advocate
Pulmatrix Q2 2025 Earnings: Loss Per Share Widens Amidst No Revenue DisclosureSocial Trade Signals - Newser
Pulmatrix Q2 2025 Earnings: Clinical-Stage Biotech Posts Net Loss of $0.42 per Share, Stock Rises 7.87% - The Legal Advocate
Pulmatrix (PULM) Reports Predictable Q2 2025 — EPS $-0.42 On TargetTrading Community - Newser
Pulmatrix, Inc. Q1 2026 10-Q Report: Financial Results, Merger with Eos SENOLYTIX, and Going Concern Risks - Minichart
Pulmatrix Releases Q1 2026 Financial Results - AlphaStreet
Press Release: Pulmatrix Announces First Quarter 2026 Financial Results - Moomoo
Pulmatrix Announces Q1 2026 Financial Results and Merger Agreement with Eos SENOLYTIX - Minichart
PULM: Merger with Eos SENOLYTIX announced; Q1 net loss narrows, cash at $3.3M - TradingView
Pulmatrix, Inc. 1Q 2026: Net loss $(1.17M), EPS $(0.32) — 10-Q Summary - TradingView
Pulmatrix Q1 net loss narrows, clinical development on hold - TradingView
Pulmatrix reports Q1 2026 net loss $1.17M, cash $3.3M and announces merger agreement with Eos SENOLYTIX - TradingView
Pulmatrix, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Pulmatrix (PULM) Q1 2026 shows tight cash, Eos merger and 94% pro forma dilution - Stock Titan
Pulmatrix (NASDAQ: PULM) Q1 loss, $1M raise and Eos merger plan - Stock Titan
Pulmatrix Announces First Quarter 2026 Financial Results - Fidelity
Finanzdaten der Pulmatrix Inc-Aktie (PULM)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.67%
3.59%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):